BridgeMD
REDUCE PMR: Rituximab Effect on Decreasing glUcoCorticoid Exposition in relapsing PolyMyalgia Rheumatica
EU CTIS ID: 2024-513545-37-00
What this study is testing
The main objective is to study the efficacy of treatment with rituximab in patients with relapsing polymyalgia rheumatica compared to placebo
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- A clinical diagnoses of PMR according to the 2012 EULAR/ACR classification criteria
- Re-emerging PMR symptoms and elevated ESR or CRP levels
- Unable to reduce glucocorticoid dose below 5mg/day prednisolone or equivalent.
You likely can't join if
- Treatment with systemic immunosuppressants (other than GC, MTX, leflunomide and azathioprine) 3 months prior to inclusion
- (clinical) suspect concomitant giant cell arteritis or other rheumatic inflammatory disease
- Concomitant conditions that might significantly interfere with evaluation of PMR pain or movement as judged by the investigator
- Previous hypersensitivity for RTX or contra-indications to RTX
- Not being able to speak, read or write Dutch
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.